Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis

被引:16
作者
Kruis, Wolfgang [1 ]
Neshta, Viacheslav [2 ]
Pesegova, Marina [3 ]
Alekseeva, Olga [4 ]
Andreev, Pavel [5 ]
Datsenko, Oleksii [6 ]
Levchenko, Olena [7 ]
Abdulkhakov, Sayar [8 ,9 ]
Lozynskyy, Yuriy [10 ]
Mostovoy, Yuriy [11 ]
Soloviev, Konstantin [12 ]
Dorofeyev, Andrey E. [13 ]
Vieth, Michael [14 ]
Stiess, Michael [15 ]
Greinwald, Roland [15 ]
Mohrbacher, Ralf [15 ]
Siegmund, Britta [16 ]
机构
[1] Evangel Krankenhaus Kalk, Dept Med, Cologne, Germany
[2] Dept Clin Hosp Railway Stn Zaporizhzhya 2 State E, Zaporizhya, Ukraine
[3] Reg Clin Hosp, Krasnoyarsk, Russia
[4] Nizhny Novgorod Reg Clin Hosp Semashko, Nizhnii Novgorod, Russia
[5] Railway Clin Hosp Stn Samara, Samara, Russia
[6] Kharkiv City Clin Hosp 2, Kharkov, Ukraine
[7] Odesa Reg Clin Hosp, Odesa, Ukraine
[8] Kazan Volga Reg Fed Univ, Kazan, Russia
[9] Kazan State Med Univ, Kazan, Russia
[10] Lviv Reg Clin Hosp, Lvov, Ukraine
[11] Private Small Scale Enterprise Pulse, Vinnitsya, Ukraine
[12] Novgorod Reg Clin Hosp, Veliklynovogorod, Russia
[13] Natl Med Univ, Kiev, Ukraine
[14] Klinikum Bayreuth, Inst Pathol, Bayreuth, Germany
[15] Dr Falk Pharma GmbH, Res & Dev, Freiburg, Germany
[16] Charite Univ Med Berlin, Med Klin Gastroenterol Infektiol Rheumatol, Berlin, Germany
关键词
RCT; Ulcerative Colitis; Inflammatory Bowel Disease; Mesalazine; 5-AMINOSALICYLIC ACID; MESALAZINE ENEMAS; MMX MESALAMINE; CLINICAL-TRIAL; COLITIS; REMISSION; THERAPIES; MILD; FOAM; INDUCTION;
D O I
10.1016/j.cgh.2018.04.027
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Although proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms. Topical mesalamine, the standard treatment, is not always effective. We conducted a randomized phase 2 trial to determine the efficacy and safety of 2 doses of a budesonide suppository vs mesalamine suppositories vs combined budesonide and mesalamine suppositories for proctitis. METHODS: We performed a prospective, double-blind, double-dummy, multicenter trial in 337 patients with active proctitis to compare the efficacies of 4 different suppository treatments. Patients were randomly assigned to groups given 2 mg budesonide suppositories (2 mg BUS; n = 89 patients), 4 mg BUS (n = 79), 1 g mesalamine suppositories (1 g MES; n = 81), or the combination of 2 mg BUS and 1 g MES (n = 88). The study was performed from November 2013 through July 2015 at 36 study sites in Europe and Russia. The primary end point was the time to resolution of clinical symptoms, defined as the first of 3 consecutive days with a score of 0 for rectal bleeding and stool frequency. RESULTS: The mean time to resolution of symptoms in the 4 mg BUS (29.8 days) and combination of 2 mg BUS and 1 g MES (29.3 days) groups resembled that of the standard 1 g MES treatment (29.2 days), but was significantly longer in the 2 mg BUS group (35.5 days). Furthermore, proportions of patients with deep, clinical, and endoscopic remission, as well as mucosal healing, were similar among the 1 g MES, 4 mg BUS, and combination therapy groups, but significantly lower in the group that received 2 mg BUS. No safety signals were observed, and the patients' treatment acceptance was high (67%-85% of patients). CONCLUSIONS: In a multicenter randomized trial, we found that the efficacy and safety of 4 mg BUS in treatment of active proctitis did not differ significantly from those of 1 g MES. Budesonide suppositories offer an alternative therapy to mesalamine for topical treatment of proctitis.
引用
收藏
页码:98 / +
页数:13
相关论文
共 31 条
[1]   Clinical Trial: A Novel High-dose 1 g Mesalamine Suppository (Salofalk) Once Daily Is as Efficacious as a 500-mg Suppository Thrice Daily in Active Ulcerative Proctitis [J].
Andus, Tilo ;
Kocjan, Andreas ;
Mueser, Moritz ;
Baranovsky, Andrey ;
Mikhailova, Tatyana L. ;
Zvyagintseva, Tatyana D. ;
Dorofeyev, Andrey E. ;
Lozynskyy, Yurii S. ;
Cascorbi, Ingolf ;
Stolte, Manfred ;
Vieth, Michael ;
Dilger, Karin ;
Mohrbacher, Ralf ;
Greinwald, Roland .
INFLAMMATORY BOWEL DISEASES, 2010, 16 (11) :1947-1956
[2]  
[Anonymous], COCHRANE DATABASE SY
[3]   Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis [J].
Boyle, Marie ;
Ting, Amanda ;
Cury, Didia B. ;
Nanda, Kavinderjit ;
Cheifetz, Adam S. ;
Moss, Alan .
INFLAMMATORY BOWEL DISEASES, 2015, 21 (12) :2873-2878
[4]   SPREAD AND DISTRIBUTION OF 5-ASA COLONIC FOAM AND 5-ASA ENEMA IN PATIENTS WITH ULCERATIVE-COLITIS [J].
CAMPIERI, M ;
CORBELLI, C ;
GIONCHETTI, P ;
BRIGNOLA, C ;
BELLUZZI, A ;
DIFEBO, G ;
ZAGNI, P ;
BRUNETTI, G ;
MIGLIOLI, M ;
BARBARA, L .
DIGESTIVE DISEASES AND SCIENCES, 1992, 37 (12) :1890-1897
[5]   5-AMINOSALICYLIC ACID AS ENEMAS OR SUPPOSITORIES IN DISTAL ULCERATIVE-COLITIS [J].
CAMPIERI, M ;
GIONCHETTI, P ;
BELLUZZI, A ;
BRIGNOLA, C ;
TABANELLI, GM ;
MIGLIOLI, M ;
BARBARA, L .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1988, 10 (04) :406-409
[6]   Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis [J].
Cohen, Russell D. ;
Dalal, Sushila R. .
INFLAMMATORY BOWEL DISEASES, 2015, 21 (07) :1719-1736
[7]   Topical Therapies in Inflammatory Bowel Disease [J].
Frei, Pascal ;
Biedermann, Luc ;
Manser, Christine N. ;
Wilk, Maike ;
Manz, Michael ;
Vavricka, Stephan R. ;
Rogler, Gerhard .
DIGESTION, 2012, 86 :36-44
[8]   Aminosalicylates [J].
Gross, Volker .
DIGESTIVE DISEASES, 2012, 30 (01) :92-99
[9]  
HANAUER S, 1993, AM J GASTROENTEROL, V88, P1188
[10]   Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study [J].
Hanauer, SB ;
Robinson, M ;
Pruitt, R ;
Lazenby, AJ ;
Persson, T ;
Nilsson, LG ;
Walton-Bowen, K ;
Haskell, LP ;
Levine, JG .
GASTROENTEROLOGY, 1998, 115 (03) :525-532